Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| LUVERIS 75 I.U. POWDER FOR SOLU. FOR INJ | 75 IU | Powder and solvent for solution for injection · Intravenous use | 3 Vial | SAR 302.55 | Biological · Prescription | SERONO | Valid |
| LUVERIS 75 I.U. POWDER FOR SOLU. FOR INJ | 75 IU | Powder and solvent for solution for injection · Subcutaneous use | 10 Vial | SAR 1397.10 | Biological · Prescription | SERONO | Withdrawn by MAH · Not Marketed |
| LUVERIS 75 I.U. POWDER FOR SOLU. FOR INJ | 75 IU | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 146.05 | Biological · Prescription | SERONO | Withdrawn by MAH · Not Marketed |
Luveris in association with a follicle-stimulating-hormone (FSH) preparation is recommended for the stimulation of follicular development in women with severe luteinising-hormone (LH) and FSH deficiency. In clinical trials, these patients were defined by an endogenous serum LH level <1.2 IU/l.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| LUVERIS | 02269066 | 75 UNIT / VIAL | POWDER FOR SOLUTION · SUBCUTANEOUS | EMD SERONO, A DIVISION OF EMD INC., CANADA |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.